DAPA

DAPA (Diagnostic and Prognostic Applications) is an Italian biotechnology company and a spin-off from the University of Florence, specializing in the development of innovative diagnostic and prognostic tools for oncology. The company focuses on targeting tumor hypoxia, specifically leveraging the expression of Carbonic Anhydrase IX (CAIX) as a highly specific biomarker for aggressive solid tumors. DAPA's primary business involves the creation of monoclonal antibodies and molecular probes designed for early cancer detection, patient stratification, and monitoring treatment response. By integrating advanced molecular biology with clinical diagnostics, DAPA aims to provide precision medicine solutions that improve outcomes for patients with renal cell carcinoma and other hypoxia-driven malignancies.